Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJassada Buaboonnamen_US
dc.contributor.authorNattee Narkbunnamen_US
dc.contributor.authorNassawee Vathanaen_US
dc.contributor.authorChayamon Takpraditen_US
dc.contributor.authorKamon Phuakpeten_US
dc.contributor.authorBunchoo Pongtanakulen_US
dc.contributor.authorSasima Tongsaien_US
dc.contributor.authorLa Ongsri Atchaneeyasakulen_US
dc.contributor.authorKleebsabai Sanpakiten_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.identifier.citationPediatric Hematology and Oncology. Vol.36, No.2 (2019), 73-81en_US
dc.description.abstract© 2019, © 2019 Taylor & Francis Group, LLC. Retinoblastoma is the most common intraocular malignancy in children. The aim of this study was to investigate the efficacy and toxicity of combination ifosfamide, carboplatin, etoposide, and vincristine (ICEV) in advanced-stage pediatric retinoblastoma [International Classification of Retinoblastoma (ICRB) group D or E], and in ICRB group C in the second eye in simultaneously treated bilateral retinoblastoma. The medical records of retinoblastoma patients treated with concurrent ICEV regimen and focal therapy were retrospectively reviewed. The ICEV treatment protocol was, as follows: ifosfamide 1800 mg/m2 on Days 1–3; MESNA 600 mg/m2 on Days 1–3; carboplatin 560 mg/m2 on Day 1; etoposide 150 mg/m2 on Days 1–3; and vincristine 1.5 mg/m2 on Day 1. Of 16 retinoblastoma patients, 13 had bilateral disease. Seven first eyes in bilateral disease that were enucleated prior to ICEV therapy were excluded. Twenty-two eyes were finally included (six group C, six group D, and ten group E). Median follow-up was 3.4 years, and the median number of ICEV courses was 7. Fifteen globes could be salvaged, 12 responded to ICEV (six group C, five group D, and one group E), and three unresponsive eyes could be salvaged with external beam radiation therapy (EBRT). Enucleation-free and relapse-free survival was 68.2 and 54.5%, respectively. The results of this study suggest ICEV as an alternative therapeutic approach for globe salvage in pediatric retinoblastoma, especially in ICRB groups C and D with manageable acute toxicity. Further study in larger cohort is needed to confirm the effectiveness of treatment.en_US
dc.rightsMahidol Universityen_US
dc.titleOutcomes of pediatric retinoblastoma treated with ICEV regimen: A single-center studyen_US
Appears in Collections:Scopus 2019

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.